[SCHEDULE 13G/A] ADMA BIOLOGICS, INC. Amended Passive Investment Disclosure
Invesco reports 5% stake in ADMA Biologics
Invesco Ltd. filed an amended Schedule 13G reporting beneficial ownership of 11,785,202 shares of ADMA Biologics Inc common stock, representing 5.0% of the class as of 12/31/2025.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Invesco Ltd. filed an amended Schedule 13G reporting beneficial ownership of 11,785,202 shares of ADMA Biologics Inc common stock, representing 5.0% of the class as of 12/31/2025. Invesco reports sole voting power over 11,085,226 shares and sole dispositive power over 11,785,202 shares.
The shares are held of record by clients of Invesco’s investment adviser subsidiaries, including Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC, with no single individual having more than 5% economic ownership. Invesco certifies the position is held in the ordinary course of business and not to influence control of ADMA.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of ADMA (ADMA) does Invesco Ltd. report owning?
Invesco Ltd. reports beneficial ownership of 5.0% of ADMA Biologics’ common stock. This stake corresponds to 11,785,202 shares held as of December 31, 2025, according to the amended Schedule 13G filing.
How many ADMA (ADMA) shares does Invesco Ltd. control the voting for?
Invesco Ltd. reports sole voting power over 11,085,226 ADMA shares. It reports no shared voting power, indicating voting authority is held solely through its controlled investment adviser entities for these shares.
Who actually holds the ADMA (ADMA) shares reported by Invesco Ltd.?
The 11,785,202 ADMA shares are held of record by clients of Invesco’s investment advisers. Invesco files as a parent holding company, and no individual client has more than 5% economic ownership of ADMA’s common stock.
Is Invesco Ltd. seeking to influence control of ADMA (ADMA) with this stake?
Invesco certifies the ADMA shares were acquired and are held in the ordinary course of business. It states they were not acquired for the purpose of changing or influencing control of ADMA Biologics.
Which Invesco subsidiaries are associated with the ADMA (ADMA) holdings?
The filing identifies Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC as the relevant subsidiaries. These investment adviser entities hold ADMA shares on behalf of their clients.
What type of reporting person is Invesco Ltd. in the ADMA (ADMA) filing?
Invesco Ltd. is classified as a parent holding company or control person, indicated by the type code HC. The company is organized in Bermuda and files on behalf of its investment adviser subsidiaries.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
ADMA Biologics Inc
(Name of Issuer)
Common Stock
(Title of Class of Securities)
000899104
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
000899104
1
Names of Reporting Persons
Invesco Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
BERMUDA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
11,085,226.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
11,785,202.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
11,785,202.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
HC, IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ADMA Biologics Inc
(b)
Address of issuer's principal executive offices:
465 State Route 17, Ramsey, NJ 07446
Item 2.
(a)
Name of person filing:
Invesco Ltd. ("Invesco Ltd.")
(b)
Address or principal business office or, if none, residence:
1331 Spring Street NW, Suite 2500, Atlanta, GA 30309
(c)
Citizenship:
Bermuda
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
000899104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 11,785,202 shares of the Issuer which are held of record by clients of Invesco Ltd.
(b)
Percent of class:
5.0 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
11,085,226
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
11,785,202
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
However, no one individual has greater than 5% economic ownership. The shareholders of the Fund have the right to receive or the power to direct the receipt of dividends and proceeds from the sale of securities listed above.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Invesco Advisers, Inc.
Invesco Asset Management Limited
Invesco Capital Management LLC
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
